46,189 Shares in Organon & Co. (NYSE:OGN) Acquired by Caption Management LLC

Caption Management LLC acquired a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 46,189 shares of the company's stock, valued at approximately $689,000.

Several other institutional investors have also added to or reduced their stakes in OGN. Vanguard Group Inc. grew its holdings in shares of Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock valued at $453,593,000 after purchasing an additional 218,165 shares during the last quarter. Pacer Advisors Inc. boosted its position in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after buying an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Organon & Co. by 1.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company's stock worth $147,634,000 after buying an additional 136,760 shares during the last quarter. LSV Asset Management increased its holdings in shares of Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company's stock worth $112,274,000 after buying an additional 30,557 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Organon & Co. by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company's stock valued at $63,582,000 after acquiring an additional 12,110 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, CEO Kevin Ali purchased 34,000 shares of the company's stock in a transaction on Monday, May 5th. The shares were purchased at an average cost of $8.80 per share, with a total value of $299,200.00. Following the completion of the purchase, the chief executive officer now owns 282,731 shares in the company, valued at $2,488,032.80. This represents a 13.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew M. Walsh acquired 11,400 shares of Organon & Co. stock in a transaction dated Monday, May 5th. The shares were bought at an average cost of $8.82 per share, with a total value of $100,548.00. Following the transaction, the chief financial officer now owns 144,484 shares in the company, valued at approximately $1,274,348.88. This trade represents a 8.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 90,800 shares of company stock valued at $799,496. 1.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. TD Cowen upgraded Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Morgan Stanley lowered their price objective on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research note on Monday. Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Evercore ISI cut shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $18.00.

Organon & Co. Trading Up 4.9 %

Shares of OGN stock opened at $9.15 on Wednesday. Organon & Co. has a 1-year low of $8.05 and a 1-year high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of 2.75, a PEG ratio of 0.90 and a beta of 0.75. The stock has a 50-day moving average of $13.21 and a 200-day moving average of $14.82.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.13. The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.22 EPS. On average, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, May 12th. Organon & Co.'s dividend payout ratio is presently 2.78%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.